Diabetes management: lessons from around the globe Romania. S. Popa (Romania)
|
|
- Belinda Brown
- 5 years ago
- Views:
Transcription
1 Diabetes management: lessons from around the globe Romania S. Popa (Romania)
2 DIABETES MANAGEMENT: LESSONS FROM AROUND THE GLOBE ROMANIA SG Popa, M Mota, E Mota, A Mitrea
3 Agenda Premises: diabetes as a huge and growing problem PREDATORR Study Children with diabetes in Romania Therapy in type 2 diabetes (CEGEDIM data) Conclusions Acknowledgements
4 Premises Diabetes (DM) and related comorbidities are major public health problems in the new millennium in most countries Recent studies of the prevalence of DM and prediabetes were furnished only for few countries The prevalence of DM, prediabetes and other metabolic diseases has not undergone until present a rigorous scientific evaluation in Romania.
5 Diabetes is a huge and growing problem
6 and the costs to society are high and escalating Diabetes is a human and economic burden 4.9 million deaths per year 50% of deaths under 60 years of age Intersects with all dimensions of development US$612 billion 1 of worldwide healthcare expenditure
7 Agenda Premises: diabetes as a huge and growing problem PREDATORR Study Children with diabetes in Romania Therapy in type 2 diabetes (CEGEDIM data) Conclusions Acknowledgements
8 Protocol number SRDCEB/2012/001; Eudra CT Number: Beneficiaries: - Romanian Society of Diabetes, Nutrition and Metabolic Diseases (RSDNMD) - Romanian Society of Nephrology (RSN) Investigators: 101 General physician CRO: CEBIS International ( Central Laboratory for the analysis of the study: Synevo
9 PREDATORR Primary goals Estimating the prevalence of DM and pre diabetes in the adult population of Romania Estimating the prevalence of overweight and obesity in the adult population of Romania Estimating the prevalence of the chronic kidney disease in the adult population of Romania Note: Prevalence distribution of the pre-specified subgroups (eg age groups etc) is also expected.
10 PREDATORR Secondary goals Estimating the prevalence of DLP in Romania Estimating the prevalence of Hyperuricemia in Romania Estimating the prevalence of Metabolic Syndrome in the population of Romania. Estimating the prevalence of HTN in Romania CVR assessment in the population of Romania: SCORE diagram for the high-risk areas Metabolic risk evaluation through FINDRISC score
11 PREDATORR Subject inclusion Subjects were randomly assigned for screening from the list of each GP via a random number generator Inclusion criteria Subjects aged years Born and with residence in Romania Living for the past 10 years mainly in Romania Included on the list of a GP affiliated with CNAS Signing the I.C. Exclusion criteria Subjects aged <20 and >79 years Born outside Romania Living for the past 10 years mostly outside Romania Refuse or can not sign the informed consent Pregnant or breastfeeding women
12 ROMANIA at a glance - PREDATORR 2013 NGT 71.9% Prediabetes 16.5% Diabetes 11.6% Known diabetes 9. Unknown diabetes 2.4%
13 ROMANIA at a glance - PREDATORR 2013 DIABETES Diabetes in Romania (20-79 years)) Adult Romanian population (20-79 years) Number of people with diabetes Age- and sex-adjusted prevalence of diabetes Undiagnosed cases (unknown diabetes mellitus UKDM) 11.6% Age- and sex-adjusted prevalence of UKDM 2.4%
14 Diabetes worldwide Diabetes in Romania - PREDATORR 2013 (Adults years); Source: IDF Diabetes Atlas Sixth Edition 2014
15 Top 10 countries/territories for prevalence (20-79 years) 2013 and 2035 Romania PREDATORR ,6% Source: IDF Diabetes Atlas Sixth Edition 2013
16 EUROPE at a glance Romania at glance PREDATORR 2013 Source: IDF Diabetes Atlas Sixth Edition 2014
17 Diabetes surge in EUROPE PREDATORR Romania million Romania 11.6% Spain % Portugal % (Adults years) Source: IDF Diabetes Atlas Sixth Edition 2014
18 Diagnosed and undiagnosed diabetes among people aged 20 years or older, United States, 2012 Romania PREDATORR million people have diabetes (11.6% of adult Romanian population) million people have undiagnosed diabetes (20.69% of people of diabetes) Source: National Health and Nutrition Examination Survey estimates applied to 2012 U.S. Census data
19 ROMANIA at a glance - PREDATORR 2013 Prevalence of impaired glucose regulation by sex and age groups 50,4% 49,3% 35,5% 29,4% 11,5% 8, Mota M. Prevalence of Diabetes Mellitus and Prediabetes in the Adult Romanian Population: PREDATORR Study. Journal of diabetes in press (available at
20 ROMANIA at a glance - PREDATORR 2013 Prevalence of DIABETES and PREDIABETES by age groups 2 4,3% 3, 13.3% 18,9% 17,7% 27,8% 2.9% 0, 2,7% 6,9% 10, Mota M. Prevalence of Diabetes Mellitus and Prediabetes in the Adult Romanian Population: PREDATORR Study. Journal of diabetes in press (available at
21 ROMANIA at a glance - PREDATORR 2013 Prevalence of DIABETES and PREDIABETES by sex 13.6% 2,9% 9.8% 16,3% 1,9% 16,7% 10,7% 7,9% Mota M. Prevalence of Diabetes Mellitus and Prediabetes in the Adult Romanian Population: PREDATORR Study. Journal of diabetes in press (available at
22 ROMANIA at a glance - PREDATORR 2013 Prevalence of DIABETES by sex and age groups 24.3% 4,6% 20% 17% 4, 4,9% % 0 3,5% 2.4% 0,5% 1,9% 12, 1,8% 8,4% 19,7% 15,9% Mota M. Prevalence of Diabetes Mellitus and Prediabetes in the Adult Romanian Population: PREDATORR Study. Journal of diabetes in press (available at
23 Prevalence (%) of people with diabetes by age and sex, 2013 (Adults years) Source: IDF Diabetes Atlas Sixth Edition 2013
24 ROMANIA at a glance - PREDATORR 2013 PREDIABETES Prediabetes in Romania (20-79 years)) Adult Romanian (20-79 years) Number of people with prediabetes Age- and sex-adjusted prevalence of prediabetes 16.5% Mota M. Prevalence of Diabetes Mellitus and Prediabetes in the Adult Romanian Population: PREDATORR Study. Journal of diabetes in press (available at
25 Prediabetes worldwide Study population Prediabetes prevalence Observations US; 20 years 37% Prediabetes Portuguese; years 27% IFG and/or IGT Spanish; 18 years 14.8% IFG and/or IGT European; years 9. IGT Romanian; years 16.5% Prediabetes Source: National Health and Nutrition Examination Survey estimates applied to 2012 U.S. Census data Gardete-Correia L et al. First diabetes prevalence study in Portugal: PREVADIAB study. Diabet Med. 2010; 27: Soriguer F et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: The Di@bet.es Study. Diabetologia. 2012; 55: IDF Diabetes Atlas Sixth Edition 2013
26 ROMANIA at a glance - PREDATORR 2013 Prevalence of PREDIABETES by sex and age groups 26, 29,3% 18,5% 19, 8% 5,7% Mota M. Prevalence of Diabetes Mellitus and Prediabetes in the Adult Romanian Population: PREDATORR Study. Journal of diabetes in press (available at
27 Prevalence (%) of IGT (20-79 years) by age and sex, 2013 (Adults years) Source: IDF Diabetes Atlas Sixth Edition 2013
28 Agenda Premises: diabetes as a huge and growing problem PREDATORR Study Children with diabetes in Romania Therapy in type 2 diabetes (CEGEDIM data) Conclusions Acknowledgements
29 Children with diabetes in Romania 1996: National Diabetes Register of the Child 2014: 401 new cases of type 1 diabetes and 6 new cases of type 2 diabetes in children 2014: type 1 diabetes incidence was 10.7/ : 2809 Children with diabetes in Romania There is a public hospital specialized in pediatric diabetes (Medical Center "Cristian Serban" European Centre of Excellence in Pediatric Diabetes in 2011). Vlad A ONROCAD Study group, 2015.
30 Agenda Premises: diabetes as a huge and growing problem PREDATORR Study Children with diabetes in Romania Therapy in type 2 diabetes (CEGEDIM data) Conclusions Acknowledgements
31 Type of therapy for type 2 diabetes patients 18% 13% 45% 47% Diet Polytherapy Bitherapy Monotherapy 36% 38% TOTAL = 1409 PATIENTS (weighted) Bitherapy includes fixed combinations
32 Type of therapy Classes in monotherapy BIGUANIDES 66% 6 SULPHONYLUREAS INSULINS 16% 2 14% 13% AGI DPP-IV INHIBITORS GLP-1 AGONISTS GLINIDES GLITAZONES 0,4% 0,40% 0,10% Displaying categories >
33 Type of therapy, Classes in bitherapy BIGUANIDES+SULPHONYLUREAS 35% 39% BIGUANIDES+INSULINS 24% 24% INSULINS+INSULINS 9% 1 DPP-IV INHIBITORS+BIGUANIDES 6% 9% SULPHONYLUREAS+INSULINS 5% 5% BIGUANIDES+GLP-1 AGONISTS 4% BIGUANIDES+AGI Displaying categories >
34 Type of therapy, Classes in polyherapy BIGUANIDES+SULPHONYLUREAS+INSULINS BIGUANIDES+INSULINS+INSULINS DPP-IV INHIBITORS+BIGUANIDES+SULPHONYLUREAS AGI+BIGUANIDES+SULPHONYLUREAS 18% 10% 13% 9% 10% 26% 3 29% BIGUANIDES+GLP-1 AGONISTS+SULPHONYLUREAS 6% DPP-IV INHIBITORS+BIGUANIDES BIGUANIDES+INSULINS BIGUANIDES+AGI+INSULINS BIGUANIDES+BIGUANIDES BIGUANIDES+SULPHONYLUREAS+GLITAZONES 5% 4% 5% Displaying categories >
35 Type of therapy Brands Brands in monotherapy SIOFOR DIAPREL METFOGAMMA LANTUS GLUCOPHAGE GLURENORM metforminum NOVOMIX AMARYL HUMALOG LEVEMIR GLUCOBAY HUMULIN JANUVIA 48% 9% 9% 6% 4% 4% 3% 4 13% 1 4% 4% 3% 3% 3% 3% 0,4% DIAPREL+SIOFOR LANTUS+SIOFOR JANUVIA+SIOFOR AMARYL+SIOFOR SIOFOR+LEVEMIR DIAPREL+METFOGAMMA NOVOMIX 30+SIOFOR GLIBOMET LEVEMIR+NOVORAPID SIOFOR+GLUCOBAY LANTUS+APIDRA METFOGAMMA+LANTUS NOVORAPID+LANTUS HUMALOG+LANTUS BYDUREON+SIOFOR 20% 8% 7% 6% 4% 4% 4% 3% 18% 7% 4% 1 4% 4% 4% 8% LANTUS+DIAPREL+SIOFOR DIAPREL+SIOFOR+LEVEMIR SIOFOR+AMARYL+LANTUS JANUVIA+SIOFOR+AMARYL SIOFOR+DIAPREL+JANUVIA SIOFOR+AMARYL+GLUCOBAY GLUCOBAY+SIOFOR+DIAPREL JANUVIA+GLIBOMET LEVEMIR+NOVORAPID+SIOFOR LEVEMIR+AMARYL+SIOFOR BYDUREON+DIAPREL+SIOFOR BYETTA+DIAPREL+SIOFOR SIOFOR+NOVORAPID+LANTUS LANTUS+GLIBOMET SIOFOR+LANTUS+APIDRA AMARYL+METFOGAMMA+LANTUS SIOFOR+APIDRA+LANTUS 9% 6% 5% 5% 4% 4% 4% 4% 3% 3% 3% 6% 1 4% 7% 5% 3% 3% 4% 3% Brands in bitherapy Brands in polytherapy Displaying categories >
36 Agenda Premises: diabetes as a huge and growing problem PREDATORR Study Children with diabetes in Romania Therapy in type 2 diabetes (CEGEDIM data) Conclusions Acknowledgements
37 Conclusions The PREDATORR study, for the first time, provides data for Romania on the prevalence of DM and prediabetes and their relationship with important risk factors in a representative sample of the Romanian adult population. The final data of the PREDATORR study indicate an increased prevalence of diabetes and prediabetes, which has doubled compared to previous estimations These results are of high value for the health authorities and can be used to help inform decision making in order to initiate the implementation of prevention programs that may reduce the economic burden of DM in Romania.
38 Agenda Premises: diabetes as a huge and growing problem PREDATORR Study Children with diabetes in Romania Therapy in type 2 diabetes (CEGEDIM data) Conclusions Acknowledgements
39 Acknowledgements Sponsors: Romanian Society of Diabetes Nutrition and Metabolic Diseases (RSDNMD), IHS Sofmedica, Abbott, Astra Zeneca, Novo Nordisk, MSD, Servier, Novartis, Worvag Pharma The Company CEBIS International ( for: Study Documentation Development, Feasibility, Project Management, Monitoring, Data Management, Statistical Analysis and Final Report Profesor Cristian Baicus - Head of the Clinical Epidemiology Unit of Bucharest, in the RECIF (Reseau d Epidemiologie Clinique International Francophone) and INCLEN (International Clinical Epidemiology Network) for review / validation of the statistical analysis Synevo Central Laboratory, for performing the analysis of the study Those 101 general physicians who who enrolled the participants, filled in the study questionnaires, and collected blood and urine samples from the participants
Epidemiology of Diabetes Mellitus in Asia
Epidemiology of Diabetes Mellitus in Asia Nam H. Cho Professor of Preventive Medicine Director of Clinical Epidemiology Ajou University School of Medicine and Hospital, Suwon Korea President-elect of International
More informationWhat the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin
Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team
More informationDiabetes - The Facts
Diabetes - The Facts What is Diabetes? In people with diabetes, blood glucose levels are higher than normal because the body either does not produce enough insulin or cannot use insulin properly. The body
More informationPrimary Prevention of T2DM. KW Chan Endocrine & Diabetes Team Department of M&G, PMH 22 March 2009
Primary Prevention of T2DM KW Chan Endocrine & Diabetes Team Department of M&G, PMH 22 March 2009 Primary Prevention of T2DM Why to intervene? When to intervene? Lifestyle intervention Pharmacological
More informationCreating Better Health
Creating Better Health With the Diabetes Prevention Program (DPP) [date] Presented by: [Presenter name/logo] Agenda Introductions Diabetes and prediabetes facts Health and financial cost of diabetes How
More informationHow they work and when to take them. Diabetes Medications
How they work and when to take them Diabetes Medications BIGUANIDES Metformin Actions Slows down the release of glucose from the liver. Helps the bodies cells become more sensitive to insulin. Pros Weight
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationDiabetes Mellitus Aeromedical Considerations. Aviation Medicine Seminar Bucharest, Romania. 11 th to 15 th November 2013
Diabetes Mellitus Aeromedical Considerations Aviation Medicine Seminar Bucharest, Romania. 11 th to 15 th November 2013 Metabolic, Nutritional or Endocrine disorders Applicants with metabolic, nutritional
More informationDiabetes is a condition with a huge health impact in Asia. More than half of all
Interventions to Change Health Behaviors and Prevention Rob M. van Dam, PhD Diabetes is a condition with a huge health impact in Asia. More than half of all people with diabetes live today in Asian countries,
More informationType 1 Diabetes (T1D) Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research
Type 1 Diabetes (T1D) Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research "Type 1 diabetes market size was valued at USD 25.52 billion in 2016 and is expected to exhibit rewarding
More informationAN INDIRECT EVALUATION OF THE NATIONAL PROGRAM OF DIABETES MELLITUS STUDY CASE OF ROMANIA
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2013 vol. 117, no. 2 PREVENTIVE MEDICINE - LABORATORY ORIGINAL PAPERS AN INDIRECT EVALUATION OF THE NATIONAL PROGRAM OF DIABETES MELLITUS STUDY CASE OF ROMANIA Maria
More informationThe Diabetes Guidelines Trek: The Next Generation. Inpatient Diabetes Guidelines. Learning Objectives. Current Inpatient Guidelines
The Diabetes Guidelines Trek: The Next Generation J. Christopher Lynch, PharmD, BCACP Southern Illinois University Edwardsville School of Pharmacy Susan Cornell BS, PharmD, CDE, FAPhA, FAADE Midwestern
More informationThe clinical and economic benefits of better treatment of adult Medicaid beneficiaries with diabetes
The clinical and economic benefits of better treatment of adult Medicaid beneficiaries with diabetes September, 2017 White paper Life Sciences IHS Markit Introduction Diabetes is one of the most prevalent
More informationInsulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
More informationThe Global Agenda for the Prevention of Diabetes: Research Opportunities
The Global Agenda for the Prevention of Diabetes: Research Opportunities William H. Herman, MD, MPH Stefan S. Fajans/GlaxoSmithKline Professor of Diabetes Professor of Internal Medicine and Epidemiology
More informationDiabetes School October 2016
Diabetes School October 2016 Name Change- Why? Shorter Has my name in it Emphasizes a major part of the practice Still see non-research patients Novo Nordisk Lilly sanofi aventis! Thank You to our LucasResearch
More informationWhy Do We Treat Obesity? Epidemiology
Why Do We Treat Obesity? Epidemiology Epidemiology of Obesity U.S. Epidemic 2 More than Two Thirds of US Adults Are Overweight or Obese 87.5 NHANES Data US Adults Age 2 Years (Crude Estimate) Population
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationDiabetes Mellitus: Overview and Guidelines
Diabetes Mellitus: Overview and Guidelines Rezvan Salehidoost, M.D., Endocrinologist Abidi Diabetes Master Class IMPORTANCE? Why is it interesting to do research in diabetes J. Olefsky, JAMA 2001:285:628-632
More informationComplete Sleep Apnea Care and Diabetes A Study on Total Cost Savings
A Study on Total Cost Savings Our Leadership In Sleep Apnea Care Nevada Sleep Diagnostics, Inc. has a fifteen year history of leadership in sleep apnea care. Nevada Sleep Diagnostics consistently raises
More informationA Guidance Statement from the American College of Physicians
Hemoglobin A1c Targets for Glycemic Control with Pharmacologic Therapy in Non-Pregnant Adults with Type 2 Diabetes Mellitus: A Guidance Statement from the American College of Physicians Timothy J. Wilt,
More informationINSULIN 101: When, How and What
INSULIN 101: When, How and What Alice YY Cheng @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form
More informationSCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
More informationFRANKFURT SITE TOUR 2017
FRANKFURT SITE TOUR 2017 MEDIA INFORMATION FRANKFURT SITE TOUR 2017 CONTENTS FRANKFURT INSULIN CITY... 4 5 DIABETES BACKGROUNDER... 6 DIABETES STATISTICS... 7 DIABETES MEDICINES... 8 IMAGE BANK... 9 NOTES...
More informationClinical Guidelines. Management of adult patients with diabetes undergoing endoscopic procedures
Clinical Guidelines Management of adult patients with diabetes undergoing endoscopic s Document Detail Document type Clinical Guideline Management of adult Patients with diabetes Undergoing Document name
More informationDiabetes management: lessons from around the globe MENA. J. Belkhadir (Morocco)
Diabetes management: lessons from around the globe MENA J. Belkhadir (Morocco) Managing Diabetes: challenges faced in the MENA Region and strategies developed Jamal Belkhadir Diabetologist, Endocrinologist
More informationUPDATE: Screening and Coverage for Diabetes and Prediabetes. Karin Gillespie, Changing Diabetes Policy, Novo Nordisk
UPDATE: Screening and Coverage for Diabetes and Prediabetes Karin Gillespie, Changing Diabetes Policy, Novo Nordisk 2 USPSTF Diabetes Screening Guideline New USPSTF Abnormal Blood Glucose and Type 2 Diabetes
More informationTABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations
177 TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary Coverage Indication for use with: INSULIN THERAPY NS NB NL PE ADULTS PEDIATRICS PREGNANCY BOLUS
More informationCardiovascular & Metabolism James List, M.D., Ph.D. Global Therapeutic Area Head, Cardiovascular & Metabolism
Cardiovascular & Metabolism James List, M.D., Ph.D. Global Therapeutic Area Head, Cardiovascular & Metabolism Cardiovascular & Metabolism 1 Our Vision for the Future To improve the lives of the millions
More informationType 2 Diabetes Mellitus hypoglycaemic agents
Type 2 Diabetes Mellitus hypoglycaemic agents Name Metformin Drug Name (eg brand name) Metformin (Diaformin Diabex) Cost / PBS per 28d mth $10.24 (1.5g dly) 1000mg+500mg / $4.44+$5.80 Concerns? Lactic
More informationPrediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes!
Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes! Jaini Patel, PharmD, BCACP Assistant Professor of Pharmacy Practice Midwestern University Chicago College of Pharmacy Kathleen
More informationBiomarkers and undiagnosed disease
Biomarkers and undiagnosed disease Soham Al Snih, MD, Ph.D The University of Texas Medical Branch, Galveston, TX May 29, 2015 Mexico City, Mexico Biomarkers Broad subcategory of medical signs Objective
More informationThe Diabetes Pandemic
The Diabetes Pandemic Madiha Abdel-Maksoud, MD, PhD, MSPH Department of Epidemiology, and The Center for Global Health Colorado School of Public Health University of Colorado Denver UNIVERSITY OF COLORADO
More informationTABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations
177 TABLE 1A: Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations TABLE 1A : Formulary Coverage of Insulin Therapies & Indications for Use in Various Populations Formulary
More informationThis slide set provides an overview of the impact of type 1 and type 2 diabetes mellitus in the United States, focusing on epidemiology, costs both
This slide set provides an overview of the impact of type 1 and type 2 diabetes mellitus in the United States, focusing on epidemiology, costs both direct and indirect and the projected burden of diabetes,
More informationPrediabetes Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes! Disclosures/Conflict of Interest.
Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes! Jaini Patel, PharmD, BCACP Assistant Professor of Pharmacy Practice Midwestern University Chicago College of Pharmacy Kathleen
More informationSIOFOR mg film-coated tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER SIOFOR 850 850mg film-coated tablets METFORMIN HYDROCHLORIDE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for
More informationGlucose Control and Prevention of Cardiovascular Disease
Glucose Control and Prevention of Cardiovascular Disease Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Diabetes Update+, March
More informationDrug Effectiveness Review Project Summary Report Long acting Insulins
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More informationRPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics
Nov/Dec 2015 Issue 11 RPCC Pharmacy Forum Special Interest Articles: Diabetes Medication Chart Insulin Chart Afreeza Did you know? Exanatide, marketed as Byetta, is the synthetic form of exendin-4, which
More informationPre-diabetes. Dr Neel Basudev. GPSI Lambeth DICT, Diabetes Lead Lambeth CCG
Pre-diabetes Dr Neel Basudev GPSI Lambeth DICT, Diabetes Lead Lambeth CCG The Prevention of Diabetes Where has this come from? Pre-diabetes mellitus (PDM) Term introduced by Tommy G. Thompson (Health &
More informationHelpful Hints for Taking Care of Your Diabetes. Farahnaz Joarder, MD and Don Kain, MA, RD,CDE Harold Schnitzer Diabetes Health Center
Helpful Hints for Taking Care of Your Diabetes Farahnaz Joarder, MD and Don Kain, MA, RD,CDE Harold Schnitzer Diabetes Health Center Objectives How big of a problem is diabetes? What is diabetes? How is
More informationObesity and Type 2 Diabetes: A Public Health Priority
Obesity and Type 2 Diabetes: A Public Health Priority Dr Iveta Nagyova 1. European Public Health Association - EUPHA 2. PJ Safarik University in Kosice, Slovakia Department of Social and Behavioural Medicine
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationOld oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy
Old oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy Melpomeni Peppa Assistant Professor of Endocrinology 2 nd Dept of Internal Medicine-Propaedeutic, Athens
More informationBARIATRIC SURGERY AND TYPE 2 DIABETES MELLITUS
BARIATRIC SURGERY AND TYPE 2 DIABETES MELLITUS George Vl Valsamakis European Scope Fellow Obesity Visiting iti Associate Prof Warwick Medical School Diabetes is an increasing healthcare epidemic throughout
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationNovember 20, Ms. Seema Verma Administrator Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, MD 21244
November 20, 2017 Ms. Seema Verma Administrator Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 Dear Administrator Verma: The Diabetes Advocacy Alliance (DAA) appreciates
More informationInitiation and Adjustment of Insulin Regimens for Type 2 Diabetes
Types of Insulin Rapid-acting insulin: lispro (Humalog), aspart (NovoRapid), glulisine (Apidra) Regular short-acting insulin: Humulin R, Novolin ge Toronto, Hypurin Regular Basal insulin: NPH (Humulin
More information3. Cardiovascular Disease?
Swiss recommendations 2016 Swiss Society of Endocrinology and Diabetology 1. Deficiency? Basal Premixed- Basal + GLP-1 RA (Xultophy ) or Basal Bolus 2. egfr < 30 ml/min? 3. Cardiovascular Disease? 4. Heart
More informationThe Diabetes Prevention Program: Call for Action
The Diabetes Prevention Program: Call for Action Osama Hamdy, MD, PhD, FACE Medical Director, Obesity Clinical Program, Director of Inpatient Diabetes Management, Joslin Diabetes Center Harvard Medical
More informationKetut Suastika. Faculty of Medicine, Udayana University< Denpasar, Bali, Indonesia
Australia-Indonesia Science Symposium Health Workshop Australia Academic of Science Canberra, 28th-30th November 2016 Ketut Suastika Faculty of Medicine, Udayana University< Denpasar, Bali, Indonesia Prevalence
More informationBackground USPSTF Guideline
July 26, 2016 The Honorable Sylvia M. Burwell The Honorable Tom Perez Secretary, Department of Health and Human Services Secretary, Department of Labor 200 Independence Ave SW 200 Constitution Avenue,
More informationLiraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationDiabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs
Diabesity Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Abdominal obesity Low HDL, high LDL, and high triglycerides HTN High blood glucose (F>100l,
More informationDiabetes in Pregnancy
Diabetes in Pregnancy Ebony Boyce Carter, MD, MPH Division of Maternal Fetal Medicine Washington University School of Medicine Disclosures I have no financial disclosures to report. Objectives Review the
More informationDOCTORAL THESIS ABSTRACT The study of diabetes and cardiometabolic risk in Romanian population
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA DOCTORAL THESIS ABSTRACT The study of diabetes and cardiometabolic risk in Romanian population PhD Supervisor: Prof. Univ. Dr. MARIA MOȚA PhD Student: SANDU
More informationDiabetes Mellitus. Medical Management and Latest Developments Dr Ahmad Abou-Saleh
Diabetes Mellitus Medical Management and Latest Developments Dr Ahmad Abou-Saleh What is Diabetes Mellitus? A disease characterised by a state of chronic elevation of blood glucose levels due to: - The
More informationRisk Monitor How-to guide
Risk Monitor How-to guide Contents INTRODUCTION... 3 RESEARCH METHODS... 4 THE RISK MONITOR... 5 STEP-BY-STEP GUIDE... 6 Definitions... 7 PHASE ONE STUDY PLANNING... 8 Define the target population... 8
More informationMicrovascular complications in the metabolic syndrome
Microvascular complications in the metabolic syndrome Dr. Chih Hao Chen Ku, FACE Endocrinology Department, San Juan de Dios Hospital Clinical Pharmacology and Toxicology Department, University of Costa
More informationNavigating the New Options for the Management of Type 2 Diabetes
Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of
More informationPsychosocial Issues for People with Diabetes. Richard Arakaki, M.D. Phoenix Area Diabetes Consultant June 28, 2017
Psychosocial Issues for People with Diabetes Richard Arakaki, M.D. Phoenix Area Diabetes Consultant June 28, 2017 Objectives Provide epidemiological and interventional data of DM in AI/AN and general population
More informationPrevalence of Diabetes Mellitus among Non-Bahraini Workers Registered in Primary Health Care in Bahrain
Prevalence of Diabetes Mellitus among Non-Bahraini Workers Page 1 of 10 Bahrain Medical Bulletin, Vol.25, No.1, March 2003 Prevalence of Diabetes Mellitus among Non-Bahraini Workers Registered in Primary
More informationMicrovascular complications in the metabolic syndrome
Microvascular complications in the metabolic syndrome Dr. Chih Hao Chen Ku, FACE Endocrinology Department, San Juan de Dios Hospital Clinical Pharmacology and Toxicology Department, University of Costa
More informationAbout The Report. imarc. Key Questions Answered in this Report:
About IMARC For more than 5 years, the International Market Analysis Research and Consulting Group has been a leading advisor on management strategy and market research worldwide. We partner with clients
More informationDiabetes Overview. Basics of Diabetes
Diabetes Overview Basics of Diabetes Objectives Review the prevalence of diabetes, how it develops and the risk of developing diabetes Review diabetes diagnosis Identify the key areas of medically managing
More informationThe health economic landscape of cancer in Europe
1 Approval number The health economic landscape of cancer in Europe Bengt Jönsson, Professor Emeritus of Health Economics Stockholm School of Economics 2 Disclaimer This presentation was developed by Professor
More informationDiabetes 101: A Brief Overview of Diabetes and the American Diabetes Association
Diabetes 101: A Brief Overview of Diabetes and the American Diabetes Association What Happens When We Eat? After eating, most food is turned into glucose, the body s main source of energy. Normal Blood
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationDr Aftab Ahmad Consultant Diabetologist at Royal Liverpool University Hospital Regional Diabetes Network Lead
Dr Aftab Ahmad Consultant Diabetologist at Royal Liverpool University Hospital Regional Diabetes Network Lead Today s Presentation HbA1c & diagnosing Diabetes What is Impaired Glucose & IGR? Implications
More informationNew Therapies for Diabetes
Type 2 diabetes is increasingly prevalent New Therapies for Diabetes Lynn Mack, M.D. Associate Professor Diabetes, Endocrinology, & Metabolism The Nebraska Medical Center lmack@unmc.edu No Conflicts of
More informationD. Hilton. Keywords Epidemiological methods, aging, prevalence.
Computational Methods in Official Statistics with an Example on Calculating and Predicting Diabetes Mellitus [DM] Prevalence in Different Age Groups within Australia in Future Years, in Light of the Aging
More informationDIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents
overview of pharmacologic agents used in the management of DIABETES Kyle Roberts, Pharm.D. PGY-1 Pharmacy Resident Saint Alphonsus RMC 1. List the different classes of diabetes medications, including the
More informationCURRENT CONTROVERSIES IN DIABETES CARE
CURRENT CONTROVERSIES IN DIABETES CARE Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact
More informationType 2 Diabetes in Adolescents
Type 2 Diabetes in Adolescents Disclosures Paid consultant, Eli Lilly, Inc, Pediatric Type 2 Diabetes Clinical Trials Outline The burden of diabetes Treatment and Prevention Youth Diabetes Prevention Clinic
More informationDiabetes: Facts and Numbers, 2014
Diabetes: Facts and Numbers, 2014 Epidemiology of Diabetes Diabetes Control and Treatment Geographical Regions and Diabetes Diabetes Costs Epidemiology of Diabetes Prevalence of Diabetes Prevalence of
More informationIndividualizing Type 2 Diabetes Management. Cynthia Gerstenlauer, ANP-BC, GCNS-BC, CDE, CCD
Individualizing Type 2 Diabetes Management Cynthia Gerstenlauer, ANP-BC, GCNS-BC, CDE, CCD Harsh Statistics 30.3 million (9.4% of population) in US had DM in 2015 The percent of population with DM increases
More informationLooking Toward State Health Assessment.
CONNECTICUT DEPARTMENT OF PUBLIC HEALTH Policy, Planning and Analysis. Looking Toward 2000 - State Health Assessment. Table of Contents Glossary Maps Appendices Publications Public Health Code PP&A Main
More informationDiabetes: We ve Come a Long Way, Baby! Amy Wachter, MD Christiana Care Endocrinology March 22, 2018
Diabetes: We ve Come a Long Way, Baby! Amy Wachter, MD Christiana Care Endocrinology March 22, 2018 Title of My Talk Ancient Times Diabetes has been affecting lives for thousands of years. Egyptians in
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology The prevalence of diabetes for all age-groups worldwide was estimated to be 2.8% in 2000 and 4.4% in 2030. The total number of
More informationMerck & Co, Inc. Announced Approval of JANUVIA TM (INN: sitagliptin), a new oral treatment of diabetes, by the US FDA
October 23, 2006 Ono Pharmaceutical Co., Ltd., Public Relations Phone: +81-6-6263-5670 Banyu Pharmaceutical Co., Ltd., Public Relations Phone: +81-3-6272-1001 Merck & Co, Inc. Announced Approval of JANUVIA
More informationInsurance Providers Reduce Diabetes Risk Through CDC Program
Insurance Providers Reduce Diabetes Risk Through CDC Program ISSUE BRIEF JULY 2018 KEY TAKEAWAYS 86 million Americans 1 in 3 adults have pre-diabetes. Studies show that losing 5 to 7 percent of body weight
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationType 2 Diabetes Mellitus in Adolescents PHIL ZEITLER MD, PHD SECTION OF ENDOCRINOLOGY DEPARTMENT OF PEDIATRICS UNIVERSITY OF COLORADO DENVER
Type 2 Diabetes Mellitus in Adolescents PHIL ZEITLER MD, PHD SECTION OF ENDOCRINOLOGY DEPARTMENT OF PEDIATRICS UNIVERSITY OF COLORADO DENVER Yes! Is Type 2 diabetes the same in kids as in adults? And No!
More informationObjectives. Type 2 Diabetes: Treating an Epidemic. Angela R. Newsome, Pharm.D Mission Hospitals/MAHEC Asheville, NC April 20, 2006
Type 2 Diabetes: Treating an Epidemic Angela R. Newsome, Pharm.D Mission Hospitals/MAHEC Asheville, NC April 20, 2006 Objectives Discuss the health and economic burden of diabetes Discuss necessary lifestyle
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More information11. December 2017 Marianne Birkeland Kjær
1 11. December 2017 Marianne Birkeland Kjær Presentation title Date 2 Agenda My Background Novo Nordisk Overview PhD and PostDoc opportunities How to apply for regular positions Novo Nordisk standard recruitment
More informationInformation for Patients
Information for Patients Guidance for Diabetic Persons having an OGD or Bronchoscopy This guidance is provided to assist with your preparation for your endoscopic procedure. If you feel unclear about how
More informationPharmacotherapy IV: Liraglutide for Chronic Weight Management SARAH CAWSEY MD, FRCPC 2 ND ANNUAL OBESITY UPDATE SEPTEMBER 22, 2018
Pharmacotherapy IV: Liraglutide for Chronic Weight Management SARAH CAWSEY MD, FRCPC 2 ND ANNUAL OBESITY UPDATE SEPTEMBER 22, 2018 Disclosures Faculty Assistant Clinical Professor, Department of Medicine,
More informationDiabetes and Obesity Do we have an epidemic? Laureen M Fleck, DNS, ARNP, CDE, NCSN
Diabetes and Obesity Do we have an epidemic? Laureen M Fleck, DNS, ARNP, CDE, NCSN Diabetes: Type 1 Primarily due to pancreatic beta cell destruction. Patients are prone to ketoacidosis Inability to transport
More informationDiabetes for CNAs. This course has been awarded two (2.0) contact hours. This course expires on August 31, 2017.
Diabetes for CNAs This course has been awarded two (2.0) contact hours. This course expires on August 31, 2017. Copyright 2005 by RN.com. All Rights Reserved. Reproduction and distribution of these materials
More informationType 2 diabetes how to prevent it? East of England Diabetes Mellitus Transformation and Sustainability Network 28 th March 2018
Type 2 diabetes how to prevent it? East of England Diabetes Mellitus Transformation and Sustainability Network 28 th March 2018 Dr Charles Bodmer Consultant Clinical Lead Dr Sonica Goel GP Clinical Lead
More informationBarns Medical Practice Service Specification: Diabetes
Barns Medical Practice Service Specification: Diabetes DEVELOPED June 2017 REVIEW DATE June 2019 Introduction Diabetes mellitus is a life-long progressive condition that can be controlled but not cured.
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationCurrent Diabetes Care for Internists:2011
Current Diabetes Care for Internists:2011 Petch Rawdaree, DM, MSc, DLSHTM Faculty of Medicine Vajira Hospital University of Bangkok Metropolis 19 th January 2011 ก ก 1. ก ก ก ก 2. ก ก ก ก ก 3. ก ก ก ก
More informationDonna Tomky, MSN, C-ANP, CDE, FAADE Albuquerque, New Mexico
Donna Tomky, MSN, C-ANP, CDE, FAADE Albuquerque, New Mexico Presented in Collaboration with New Mexico Health Care Takes On Diabetes Discuss the burden and challenges prediabetes presents in New Mexico.
More informationVery Practical Tips for Managing Type 2 Diabetes
Very Practical Tips for Managing Type 2 Diabetes Jean-François Yale, MD, FRCPC McGill University Health Centre, Montreal, Canada Jean-francois.yale@mcgill.ca www.dryale.ca OBJECTIVES DISCLOSURES The participant
More informationInsulins: Prices, Rebates, and Other Factors Influencing Costs. May 2018
Insulins: Prices, Rebates, and Other Factors Influencing Costs May 2018 Introduction: Types of Insulin Types of Insulin Rapid-acting: Usually taken before a meal to cover the blood glucose elevation from
More informationInvestor Update May 2016
Investor Update May 2016 Novo Nordisk poised for growth through helping care for rising global diabetes epidemic On Marsico Capital Management s trip to Australia in March, Portfolio Managers Tom Marsico
More information